Medacta Group SA (MOVE) AI Stock Analysis

• Market Cap: CHF3.12B
• Dividend Yield: 0.45%
• Average Volume (3M): 12.13K
• Price to Earnings (P/E): 34.9
• Beta (1Y): 0.81
• Revenue Growth: 16.59%
• EPS Growth: 65.76%
• Country: CH
• Employees: 1,907
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.66
• Shares Outstanding: 20,000,000
• 10 Day Avg. Volume: 8,750
• 30 Day Avg. Volume: 12,134
• PEG Ratio: 1.10
• Price to Book (P/B): 7.36
• Price to Sales (P/S): 4.88
• P/FCF Ratio: 112.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF168.00
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 5.31
• Revenue Forecast (FY): CHF770.83M

• Rating: 69 Neutral
• Price Target: CHF171.00 ▲(1.79% Upside)
• Action: Downgraded Date: 03/16/26
• Date: Action: Downgraded 03/16/26

The score is driven primarily by solid fundamentals (growth and profitability) and supportive earnings-call guidance. It is held back by volatile/limited free-cash-flow conversion, a mixed technical backdrop with negative MACD, and a demanding valuation (high P/E with low dividend yield).

Positive Factors

Sustained Revenue Growth

Multi-year top-line expansion demonstrates durable demand for Medacta's orthopedic implants and procedure-linked consumables. Procedure-driven sales across hips, knees, extremities and spine diversify revenue, supporting predictable cash flow and funding of R&D and geographic expansion over the medium term.

High and Improving Profitability

Sustained high gross and EBITDA margins indicate strong product mix, pricing power and operational efficiency in a specialized med-tech niche. Healthy margins support reinvestment in innovation, surgeon training and manufacturing scale, increasing resilience to reimbursement pressure and competitive moves.

Strengthened Balance Sheet and Returns

Rising equity, moderate leverage and a ~21% ROE signal improving capital efficiency and financial resilience. This supports strategic investments (e.g., Parcus integration, potential U.S. manufacturing) and provides flexibility for targeted M&A without overleveraging the business.

Negative Factors

Inconsistent Free Cash Flow Conversion

Uneven free cash flow versus strong accounting profits indicates working-capital swings and heavy reinvestment. Modest FCF conversion limits organic funding for capex, acquisitions and shareholder returns, making the company more reliant on external financing during expansion phases.

Margin Compression & H2 Margin Risk

A trend of compressing gross margins and guidance for a second-half EBITDA step-down (integration costs, higher expenses) implies margin volatility. Sustaining prior profitability will require successful integration, cost control and pricing discipline amid tougher comps and investment in growth initiatives.

Rising Absolute Debt Level

Although leverage ratios improved, higher absolute debt tied to growth raises interest and covenant risk and can constrain strategic optionality. Continued debt-funded expansion increases sensitivity to cash-flow swings and may limit ability to pursue opportunistic investments without re-leveraging.

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

How the Company Makes Money

Medacta primarily makes money by selling orthopedic medical devices to healthcare providers (e.g., hospitals and surgical centers) and through distribution channels that supply surgeons and institutions. Its core revenue streams are product sales of implant systems and associated components used in orthopedic surgeries, supported by related instrument sets and procedure-enabling solutions that accompany the use of those implants. Revenue is generally generated per surgical procedure through the purchase of implants and consumable components, while complementary surgical instruments and support items may be sold and/or provided as part of the overall commercial offering tied to implant adoption. Earnings are influenced by procedure volumes in target orthopedic indications, product mix (e.g., higher-value reconstructive systems), pricing and reimbursement dynamics in served markets, and the breadth/effectiveness of its sales organization and distributor network. Specific material partnerships or contract terms: null.

Medacta Group SA Financial Statement Overview

Summary

Strong multi-year revenue growth and solid profitability (healthy EBITDA/EBIT and improving net margin in 2025) support the score. Offsetting this are uneven cash generation and modest free cash flow relative to earnings, plus some margin compression versus earlier years.

Income Statement

Revenue has grown strongly over the cycle (from 302.5M in 2020 to 688.3M in 2025), with continued growth in 2025 (6.5%). Profitability is solid: 2025 gross margin is ~64% and operating profitability remains healthy (EBITDA margin ~27.7%, EBIT margin ~16.8%). Net margin improved versus 2024 (to ~14.0%), but margins have shown some compression versus earlier years (gross margin down from ~72% in 2021), which is the key watch item.

Balance Sheet

The balance sheet looks sound with equity building over time (164.7M in 2020 to 456.2M in 2025) and strong returns to shareholders (2025 return on equity ~21%). Leverage is moderate and improved versus 2020 (debt-to-equity ~0.58 in 2025 vs ~0.91 in 2020), though total debt has risen alongside growth (to 262.6M in 2025), keeping financial flexibility a point to monitor.

Cash Flow

Cash generation is positive but less consistent at the free-cash-flow line. Operating cash flow increased to 153.7M in 2025, but cash conversion remains moderate (operating cash flow is ~71% of net income in 2025). Free cash flow improved materially in 2025 (29.9M) after being very low in 2024 (2.5M) and negative in 2023 (-7.1M), and free cash flow is still a modest share of earnings (~19% in 2025), suggesting ongoing reinvestment and/or working-capital swings.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	688.27M	590.58M	510.78M	437.12M	363.13M
Gross Profit	441.40M	399.44M	347.85M	305.26M	261.25M
EBITDA	190.55M	160.51M	119.64M	106.96M	97.81M
Net Income	96.12M	72.89M	47.36M	46.25M	51.52M
Balance Sheet
Total Assets	916.93M	792.18M	695.87M	584.49M	489.27M
Cash, Cash Equivalents and Short-Term Investments	33.19M	31.59M	20.79M	32.26M	20.40M
Total Debt	262.56M	241.21M	201.98M	170.25M	132.66M
Total Liabilities	460.71M	412.51M	365.83M	309.83M	262.87M
Stockholders Equity	456.22M	379.66M	330.04M	274.65M	226.40M
Cash Flow
Free Cash Flow	29.90M	2.45M	-7.09M	10.35M	7.57M
Operating Cash Flow	153.65M	107.14M	75.13M	73.51M	54.06M
Investing Cash Flow	-137.86M	-98.87M	-80.61M	-65.11M	-52.04M
Financing Cash Flow	-18.91M	4.33M	-10.13M	3.44M	-31.21M

Medacta Group SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 168.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Positive. The current price of 168 is above the 20-day moving average (MA) of 156.42, above the 50-day MA of 159.70, and above the 200-day MA of 149.52, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 59.51 is Neutral, neither overbought nor oversold. The STOCH value of 88.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
YPSN	70 Outperform	CHF3.98B	7.66	27.15%	0.67%	27.63%	160.67%
MOVE	69 Neutral	CHF3.12B	34.95	23.76%	0.45%	16.59%	65.76%
STMN	66 Neutral	CHF12.24B	41.72	―	1.02%	4.49%	45.08%
TECN	65 Neutral	CHF1.52B	-14.70	4.57%	2.31%	-9.34%	-37.50%
MED	62 Neutral	CHF1.11B	-168.33	―	―	7.29%	-112.70%
KURN	56 Neutral	CHF917.58M	498.59	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medacta Group SA Corporate Events

Medacta Delivers Record 2025 Results and Lifts Growth Targets on Broad-Based Orthopaedics Momentum

Medacta Group SA, a Swiss orthopaedics manufacturer listed on SIX under the ticker MOVE, develops implants and surgical technologies for hip, knee, spine and extremities procedures, with a strong emphasis on minimally invasive techniques and personalized, technology-enabled solutions. The company continues to expand its global footprint, workforce and manufacturing base, including a new automated warehouse in Italy and its first non-Swiss production site in Florida.

Medacta reported record 2025 results with revenue rising 18.5% in constant currency to €683.8 million and adjusted EBITDA up 19.1% to €190.8 million, lifting the margin to 29.0% in constant currency. Growth was broad-based across all regions and product lines, highlighted by strong gains in knee and extremities and supported by innovations such as Kinematic Alignment platforms and NextAR augmented reality systems, while the Parcus Medical acquisition and capacity expansions in Italy and Switzerland underpin upgraded 2026 and mid-term growth guidance and a sharply higher dividend proposal.

The group generated a 31.0% increase in net profit to €95.5 million, a 42.5% rise in operating cash flow, and strengthened its balance sheet with higher equity and an improved equity ratio, while adding 258 employees to reach a total of 2,165 staff. By investing in supply chain optimization, vertical integration in sports medicine and ongoing production expansion, Medacta aims to sustain above-market growth and further enhance profitability, reinforcing its competitive position in the global orthopaedics market.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF185.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.

Medacta Delivers 18.5% Constant-Currency Revenue Growth in 2025 on Broad-Based Demand

Medacta Group SA reported another year of robust, above-market expansion in 2025, with preliminary unaudited revenue rising 18.5% in constant currency (15.8% in euro) to €683.8 million, driven by double-digit growth in all major regions and product lines. Asia-Pacific and North America led geographic performance with growth of 23.0% and 19.0% respectively, while Latin America surged 42.2%, and the acquisition and integration of Parcus Medical contributed roughly 1.5% to group sales; across business lines, knee and extremities posted particularly strong increases, supported by Medacta’s AMIS hip platform, Kinematic Alignment and GMK SpheriKA knee technologies, and NextAR augmented reality systems in shoulder and spine, underscoring the company’s innovation-led growth strategy, ongoing supply-chain optimization through a new automated warehouse in Italy, and continued investment in its global workforce with the creation of 258 new jobs.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF183.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.